Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

References

• International Expert Committee International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes Diabetes Care 2009 32 7 1327 1334 19502545
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 23 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• BYETTA^® exenatide injection [prescribing information] San Diego, CA Amylin Pharmaceuticals, Inc 2011
   Google Scholar
• Apovian CM Bergenstal RM Cuddihy RM Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes Am J Med 2010 123 5 468.e9 468.e17 20399326
   PubMed Web of Science ®Google Scholar
• Cervera A Wajcberg E Sriwijitkamol A Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab 2008 294 5 E846 E852 18334612
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Okerson T Viswanathan P Guan X Holcombe JH MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 2008 24 10 2943 2952 18786299
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Edwards CM Stanley SA Davis R Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 2001 281 1 E155 E161 11404233
   PubMed Web of Science ®Google Scholar
• Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 6 2131 2157 17498508
   PubMed Web of Science ®Google Scholar
• Bunck MC Corner A Eliasson B Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes Diabetes Care 2011 34 9 2041 2047 21868779
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Buse JB Klonoff DC Nielsen LL Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin Ther 2007 29 1 139 153 17379054
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 1 275 286 18053320
   PubMed Web of Science ®Google Scholar
• DeYoung MB MacConell L Sarin V Trautmann M Herbert P Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 2011 13 11 1145 1154 21751887
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Buse JB Drucker DJ Taylor KL DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 2010 33 6 1255 1261 20215461
   PubMed Web of Science ®Google Scholar
• Taylor K Gurney K Han J Pencek R Walsh B Trautmann M Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years BMC Endocr Disord 2011 11 9 21529363
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects JAMA 1997 277 11 925 926 9062334
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Ahrén B Foley JE Ferrannini E Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy Diabetes Care 2010 33 4 730 732 20067974
   PubMed Web of Science ®Google Scholar
• Kooy A de Jager J Lehert P Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus Arch Intern Med 2009 169 6 616 625 19307526
   PubMedGoogle Scholar
• Seck T Nauck M Sheng D Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study Int J Clin Pract 2010 64 5 562 576 20456211
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 2010 12 5 442 451 20415693
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks Diabetes Care 2012 35 4 683 689 22357185
   PubMed Web of Science ®Google Scholar
• Patel A ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 2007 370 9590 829 840 17765963
   PubMed Web of Science ®Google Scholar
• Ginsberg HN The ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial: what we learn from subgroup analyses Diabetes Care 2011 34 Suppl 2 S107 S108 21525439
   PubMed Web of Science ®Google Scholar
• Curb JD Pressel SL Cutler JA Systolic Hypertension in the Elderly Program Cooperative Research Group Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension JAMA 1996 276 23 1886 1892 8968014
   PubMed Web of Science ®Google Scholar
• Aalbers J ACCORD lipid study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients Cardiovasc J Afr 2010 21 2 118 119 20532440
   PubMed Web of Science ®Google Scholar
• Elam M Lovato LC Ginsberg H Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective Curr Opin Lipidol 2011 22 1 55 61 21102326
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 1998 317 7160 703 713 9732337
   PubMed Web of Science ®Google Scholar
• Gaede P Vedel P Parving HH Pedersen O Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 1999 353 9153 617 622 10030326
   PubMed Web of Science ®Google Scholar
• Gaede P Vedel P Larsen N Jensen GV Parving HH Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 2003 348 5 383 393 12556541
   PubMed Web of Science ®Google Scholar
• Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 1 150 156 21334333
   PubMed Web of Science ®Google Scholar